Literature DB >> 19007777

HDAC inhibition upregulates the expression of angiostatic ADAMTS1.

Chia-Wei Chou1, Ching-Chow Chen.   

Abstract

HDAC inhibitors are promising anticancer agents that induce cell cycle arrest and apoptosis. However, the role of HDACs in cancer progression, such as angiogenesis and metastasis, remains largely unexplored. Among various HDAC inhibitors, we demonstrate that TSA and SAHA upregulated the expression of angiostatic ADAMTS1 in A549 cells. HDAC6 inhibitor tubacin, and knockdown of HDAC6, also lead to ADAMTS1 upregulation. By reporter, DAPA, and ChIP assays, the proximal GC boxes were demonstrated to be essential for ADAMTS1 induction. Decreased binding of SP1 and HDAC6 to the ADAMTS1 promoter after TSA treatment was also seen. These data suggest the involvement of HDAC6 and SP1 in the HDACi-induced expression of angiostatic ADAMTS1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19007777     DOI: 10.1016/j.febslet.2008.10.048

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  The ADAMTS1 protease gene is required for mammary tumor growth and metastasis.

Authors:  Carmela Ricciardelli; Kate M Frewin; Izza de Arao Tan; Elizabeth D Williams; Kenneth Opeskin; Melanie A Pritchard; Wendy V Ingman; Darryl L Russell
Journal:  Am J Pathol       Date:  2011-10-12       Impact factor: 4.307

2.  Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines.

Authors:  M Lundh; D P Christensen; D N Rasmussen; P Mascagni; C A Dinarello; N Billestrup; L G Grunnet; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2010-09-28       Impact factor: 10.122

3.  Histone deacetylase inhibitors enhance endothelial cell sprouting angiogenesis in vitro.

Authors:  Guang Jin; Dirk Bausch; Thomas Knightly; Zhengcai Liu; Yongqing Li; Baoling Liu; Jennifer Lu; Wei Chong; George C Velmahos; Hasan B Alam
Journal:  Surgery       Date:  2011-09       Impact factor: 3.982

4.  Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.

Authors:  Abraham Jacob; Janet Oblinger; Matthew L Bush; Victoria Brendel; Griffin Santarelli; Abhik R Chaudhury; Samuel Kulp; Krista M D La Perle; Ching-Shih Chen; Long-Sheng Chang; D Bradley Welling
Journal:  Laryngoscope       Date:  2011-11-22       Impact factor: 3.325

5.  Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation.

Authors:  Pei-Fang Tsai; Sue-Jane Lin; Pei-Lun Weng; Shu-Chun Tsai; Jiun-Han Lin; Ya-Ching Chou; Ching-Hwa Tsai
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

6.  CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.

Authors:  Pei-Ming Yang; Pei-Jie Lin; Ching-Chow Chen
Journal:  Epigenetics       Date:  2012-04-01       Impact factor: 4.528

7.  Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line.

Authors:  Jennifer S Waby; Haridasan Chirakkal; ChenWei Yu; Gareth J Griffiths; Roderick S P Benson; Colin D Bingle; Bernard M Corfe
Journal:  Mol Cancer       Date:  2010-10-15       Impact factor: 27.401

Review 8.  Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.

Authors:  Anderly C Chueh; Janson W T Tse; Lars Tögel; John M Mariadason
Journal:  Antioxid Redox Signal       Date:  2014-03-27       Impact factor: 8.401

9.  Construction and Quantitative Validation of Chicken CXCR4 Expression Reporter.

Authors:  Masoumeh Es-Haghi; Mohammadreza Bassami; Hesam Dehghani
Journal:  Mol Biotechnol       Date:  2016-03       Impact factor: 2.695

10.  Histone deacetylase classes I and II regulate Kaposi's sarcoma-associated herpesvirus reactivation.

Authors:  Hye Jin Shin; Jennifer DeCotiis; Mario Giron; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.